Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes—GD with elevated fasting blood sugar levels.
Contrary to conventional medical wisdom, metformin compares favorably with insulin for controlling blood sugar in A2 gestational diabetes-GD with elevated fasting blood sugar levels.
Researchers randomized women at less than 36 weeks' gestation to achieve normal blood sugar levels by either subcutaneous insulin injection (0.7 units) or 500 mg of metformin, with the goal of attaining postprandial blood glucose readings of less than 120 mg/dL and fasting blood sugars of between 60 and 90 mg/dL. Pregnant women were excluded from the study if they had conditions like insulin-dependent diabetes mellitus, chronic hypertension, or seizure disorders.
Thirty-one patients received insulin injection and 32 metformin. Those receiving the latter weighed about 30 lb more than the other group. Glucose levels were similar in each group and actually somewhat lower in the metformin group 2 hours after lunch (mean 106 vs. 112.5) and 2 hours after dinner (mean 108.1 vs. 109.2). There was little difference in abdominal delivery rates, shoulder dystocia, and postpartum hemorrhage and no differences in newborn statistics between the two groups, nor in birthweight, Apgar score at 5 minutes, or NICU admission.
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More